Luke M. Judge

This paper identifies therapeutic opportunities for over 500 genes with dominant and dispensable disease alleles by enabling mutation-agnostic gene therapy through allele-specific targeting.

This paper demonstrates haplotype editing with CRISPR/Cas9 to target NEFL missense mutations in iPSC-derived motor neurons, showing therapeutic potential and challenges in disrupting mutant allele expression.

The paper investigates DNA repair in postmitotic neurons and shows that manipulating repair pathways can influence CRISPR editing outcomes.

The paper develops a cardiac microphysiological system to screen lipid nanoparticle/mRNA complexes and identifies a formulation with improved transfection efficiency and reduced off-target liver uptake.

This study investigates the functional impact of a BAG3 allele associated with reduced heart failure risk, showing it enhances cardiomyocyte stress resistance through altered protein interactions.

This paper demonstrates allele-specific CRISPR gene editing in a human CMT2E model rescues disease pathology by inactivating the mutant NEFL allele.

The paper introduces ddXR, a method to rapidly and accurately quantify DNA excisions and inversions without sequencing, revealing high rates of large excisions and low dependence on linear distance.

The paper identifies cis-regulatory chromatin contacts in neural cells and links them to genetic variants associated with complex neurological disorders.

This paper introduces DISCOVER-Seq, a method to detect CRISPR off-targets in vivo with single-base resolution, applicable to multiple Cas nucleases.